GBM is characterized by different molecular characteristics among which the amplification of the epidermal growth factor receptor (EGFR) in association with a variant of receptor EGFRvIII may cause drug and apoptosis resistance mechanisms hindering therapeutic success. The gene discussed is EGFR; the disease is glioblastoma.